AFM13

July 19, 2019July 19, 2019

Affimed Trial Updates Support AFM13 Use for Certain CD30-positive Lymphomas

News

Updated results from two clinical trials support the potential of AFM13, an investigational immunotherapy being developed by Affimed, in combination with Merck‘s Keytruda (pembrolizumab) for patients with Hodgkin’s lymphoma, or ... Read more

October 17, 2018

AFM11 Clinical Program for Lymphoma and Leukemia on Hold Over Safety Concerns

News

Affimed has placed its AFM11 Phase 1 program on clinical hold after two life-threatening events in its lymphoma trial and one death in the leukemia study, the company announced in a press release. ... Read more

June 27, 2018

Keytruda-AFM13 Combo Effective for Hodgkin’s Lymphoma, Preliminary Phase 1b Data Show

News

Treatment with Keytruda (pembrolizumab) and Affimed’s AFM13 is well-tolerated with a favorable response rate in patients with relapsed or refractory Hodgkin’s lymphoma, according to an early analysis of a Phase 1b trial. ... Read more

February 5, 2018February 5, 2018

Affimed’s AFM13 Shows High Response Rates in 2 Lymphoma Subtypes

News

AFM13, a bispecific antibody that recruits natural killer (NK) cells to the vicinity of a tumor, has shown promise in clinical trials of both Hodgkin’s lymphoma and in CD30-positive cutaneous ... Read more

January 26, 2016January 26, 2016

New Hodgkin Lymphoma Combo Therapy of Keytruda and AFM13 to Move into Clinical Trial

News

Affimed Therapeutics N.V. , a German clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reports that it has entered into an immuno-oncology clinical research collaboration with ... Read more

January 21, 2016May 13, 2016

‘Hodgkin’s Lymphoma Day’ Webcast to Discuss Affimed’s Clinical-stage Immunotherapy

News

Affimed N.V. recently announced its planned Hodgkin’s Lymphoma Day live webcast, where company executives will be joined by cancer experts to discuss developments in disease treatment and, particularly, to present Affimed’s leading Hodgkin’s lymphoma ... Read more